Glycemia, Treatment Satisfaction, Cognition, and Sleep Quality in Adults and Adolescents with Type 1 Diabetes When Using a Closed-Loop System Overnight Versus Sensor-Augmented Pump with Low-Glucose Suspend Function: A Randomized Crossover Study
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We compared glycemia, treatment satisfaction, sleep quality, and cognition using a nighttime Android-based hybrid closed-loop system (Android-HCLS) with sensor-augmented pump with low-glucose suspend function (SAP-LGS) in people with type 1 diabetes. MATERIALS AND METHODS: An open-label, prospective, randomized crossover study of 16 adults (mean [SD] age 42.1 [9.6] years) and 12 adolescents (15.2 [1.6] years) was conducted. All participants completed four consecutive nights at home with Android-HCLS (proportional integral derivative with insulin feedback algorithm; Medtronic) and SAP-LGS. PRIMARY OUTCOME: percent continuous glucose monitoring (CGM) time (00:00-08:00 h) within target range (72-144 mg/dL). Secondary endpoints: percent CGM time above target (>144 mg/dL); below target (<72 mg/dL); glycemic variability (SD); symptomatic hypoglycemia; adult treatment satisfaction; sleep quality; and cognitive function. RESULTS: The primary outcome for all participants was not statistically different between Android-HCLS and SAP-LGS (mean [SD] 59.4 [17.9]% vs. 53.1 [18]%; p = 0.14). Adults had greater percent time within target range (57.7 [18.6]% vs. 44.5 [14.5]%; p < 0.006); less time above target (42.0 [18.7]% vs. 52.6 [16.5]%; p = 0.034); lower glycemic variability (35 [10.7] mg/dL vs. 46 [10.7] mg/dL; p = 0.003); and less (median [IQR]) time below target (0.0 [0.0-0.4]% vs. 0.80 [0.0-3.9]%; p = 0.025). In adolescents, time below target was lower with Android-HCLS vs. SAP-LGS (0.0 [0.0-0.0]% vs. 1.8 [0.1-7.9]%; p = 0.011). Nocturnal symptomatic hypoglycemia was less (1 vs. 10; p = 0.007) in adolescents, but not adults (5 vs. 13; p = 0.059). In adults, treatment satisfaction increased by 10 points (p < 0.02). Sleep quality and cognition did not differ. CONCLUSIONS: Android-HCLS in both adults and adolescents reduced nocturnal hypoglycemia and, in adults, improved overnight time in target range and treatment satisfaction compared with SAP-LGS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
The problem areas in diabetes scale: an evaluation of its clinical utility
Welch, G. W., Jacobson, A. M., & Polonsky, W. H. (1997) · Diabetes Care · doi:10.2337/diacare.20.5.760 · Cited by 664 · cited 3×
“DTSQs: Diabetes Treatment Satisfaction Questionnaire status (scored 0–36); DTSQ items 2 and 3 (scored 0–6); PAID: Problem Areas in Diabetes (scored 0–100); HFS-II: Hypoglycemia Fear Survey, version 2 (scored 0–4); CHFS: Children Hypoglycemia Fear Survey (scored 0–4).”
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652 · cited 3×
“10,11 However, while suspension of insulin delivery reduces hypoglycemia, it does not directly address elevated glucose levels.”
Home Use of an Artificial Beta Cell in Type 1 Diabetes
Thabit, H., Tauschmann, M., Allen, J. M., Leelarathna, L., Hartnell, S., Wilinska, M. E., Acerini, C. L., Dellweg, S., Benesch, C., Heinemann, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509351 · Cited by 450
Ly, T. T., Nicholas, J. A., Retterath, A., Lim, E. M., Davis, E. A., & Jones, T. W. (2013) · JAMA · doi:10.1001/jama.2013.277818 · Cited by 411 · cited 1×
“10,11 However, while suspension of insulin delivery reduces hypoglycemia, it does not directly address elevated glucose levels.”
Self-citationPsychometric properties of the hypoglycemia fear survey-ii for adults with type 1 diabetes
Gonder-Frederick, L. A., Schmidt, K. M., Vajda, K. A., Greear, M. L., Singh, H., Shepard, J. A., & Cox, D. J. (2011) · Diabetes Care · doi:10.2337/dc10-1343 · Cited by 337 · cited 2×
“DTSQs: Diabetes Treatment Satisfaction Questionnaire status (scored 0–36); DTSQ items 2 and 3 (scored 0–6); PAID: Problem Areas in Diabetes (scored 0–100); HFS-II: Hypoglycemia Fear Survey, version 2 (scored 0–4); CHFS: Children Hypoglycemia Fear Survey (scored 0–4).”
Fully Integrated Artificial Pancreas in Type 1 Diabetes
Breton, M., Farret, A., Bruttomesso, D., Anderson, S., Magni, L., Patek, S., Dalla Man, C., Place, J., Demartini, S., Del Favero, S., et al. (2012) · Diabetes · doi:10.2337/db11-1445 · Cited by 315
Kovatchev, B., Cobelli, C., Renard, E., Anderson, S., Breton, M., Patek, S., Clarke, W., Bruttomesso, D., Maran, A., Costa, S., et al. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400611 · Cited by 200
Barnard, K. D., Wysocki, T., Allen, J. M., Elleri, D., Thabit, H., Leelarathna, L., Gulati, A., Nodale, M., Dunger, D. B., Tinati, T., et al. (2014) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2014-000025 · Cited by 159
Cited by
Weisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes
Rodbard, D. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0035 · Cited by 458
Bekiari, E., Kitsios, K., Thabit, H., Tauschmann, M., Athanasiadou, E., Karagiannis, T., Haidich, A.-B., Hovorka, R., & Tsapas, A. (2018) · BMJ · doi:10.1136/bmj.k1310 · Cited by 437
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
Carlson, A. L., Sherr, J. L., Shulman, D. I., Garg, S. K., Pop-Busui, R., Bode, B. W., Lilenquist, D. R., Brazg, R. L., Kaiserman, K. B., Kipnes, M. S., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0319 · Cited by 230
Self-citation
Metadata
- Authors
- Sharifi, A., De Bock, M. I., Jayawardene, D., Loh, M. M., Horsburgh, J. C., Berthold, C. L., Paramalingam, N., Bach, L. A., Colman, P. G., Davis, E. A., Grosman, B., Hendrieckx, C., Jenkins, A. J., Kumareswaran, K., Kurtz, N., Kyoong, A., MacIsaac, R. J., Speight, J., Trawley, S., Ward, G. M., Roy, A., Jones, T. W., & O'Neal, D. N.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2016-12
- Volume
- 18
- Issue
- 12
- Pages
- 772-783
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2553292368
- Cited by
- 91
- References
- 9
- FWCI
- 10.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glycemia, Treatment Satisfaction, Cognition, and Sleep Quality in Adults and Adolescents with Type 1 Diabetes When Using a Closed-Loop System Overnight Versus Sensor-Augmented Pump with Low-Glucose Suspend Function: A Randomized Crossover Study. https://app.cochat.ai/papers/10.1089/dia.2016.0288
- The paper
- Sharifi, A., De Bock, M. I., Jayawardene, D., Loh, M. M., Horsburgh, J. C., Berthold, C. L., Paramalingam, N., Bach, L. A., Colman, P. G., Davis, E. A., Grosman, B., Hendrieckx, C., Jenkins, A. J., Kumareswaran, K., Kurtz, N., Kyoong, A., MacIsaac, R. J., Speight, J., Trawley, S., . . . O'Neal, D. N. (2016). Glycemia, Treatment Satisfaction, Cognition, and Sleep Quality in Adults and Adolescents with Type 1 Diabetes When Using a Closed-Loop System Overnight Versus Sensor-Augmented Pump with Low-Glucose Suspend Function: A Randomized Crossover Study. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2016.0288
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.